SCHEMBL3162575

SCHEMBL3162575

O=C(c1ccc(S(=O)(=O)Nc2nccs2)cc1)N1CCCCC1CCn1cccn1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.49
KMT2A Q03164 6/20 0.47
MEN1 O00255 5/20 0.47
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
TSHR P16473 2/20 0.46
MAPK1 P28482 1/20 0.46
GCK P35557 2/20 0.44
KCNH2 Q12809 1/20 0.44
SCN3A Q9NY46 4/20 0.44
USP2 O75604 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
STAT3 P40763 1/20 0.42
HTT P42858 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PKM P14618 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3168484 0.81 SCN9A (0.55) SCN9AKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL3166856 0.81 SCN9A (0.53) SCN9AKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL4183948 0.80 TRPC3 (0.42) SCN9AALDH1A1SMN1; SMN2USP2MAPT
SCHEMBL14780433 0.80 SCN9A (0.48) SCN9AKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL3169013 0.79 SCN9A (0.59) SCN9AKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL3168619 0.78 SCN9A (0.52) SCN9AKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL3169260 0.77 SCN9A (0.65) SCN9AKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL3171643 0.77 SCN9A (0.54) SCN9AKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL3153937 0.77 SCN9A (0.64) SCN9AKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL3168667 0.76 SCN9A (0.61) SCN9AKMT2AMEN1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN9A 51/4885KMT2A 1920/4885MEN1 4729/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN9A 51/4885KMT2A 1920/4885MEN1 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.